Revelation Biosciences, Inc. (REVBW) stock
REVBWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVB
$0.01+0.00 (0.00%)
Close on Oct 30, 2026Market cap $16.05MP/E –Yield –
Revelation Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Revelation Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.18M, up 43.4% year over year. For fiscal 2025 it was $4.06M, up 14.5% from the year before. The highest annual figure on record is $6.91M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.06M | +14.5% |
| FY2024 | Dec 31, 2024 | $3.55M | -14.4% |
| FY2023 | Dec 31, 2023 | $4.15M | -22.9% |
| FY2022 | Dec 31, 2022 | $5.38M | -22.2% |
| FY2021 | Dec 31, 2021 | $6.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.92M | +45.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.38M | +60.3% |
| Q4 FY2025 | Dec 31, 2025 | $964.19K | +59.2% |
| Q3 FY2025 | Sep 30, 2025 | $922.86K | +11.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.32M | -5.5% |
| Q1 FY2025 | Mar 31, 2025 | $858.83K | +19.7% |
| Q4 FY2024 | Dec 31, 2024 | $605.50K | -42.9% |
| Q3 FY2024 | Sep 30, 2024 | $830.98K | -49.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.39M | +53.4% |
| Q1 FY2024 | Mar 31, 2024 | $717.58K | +36.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.06M | +211.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.65M | +332.8% |
| Q2 FY2023 | Jun 30, 2023 | $909.28K | -6.8% |
| Q1 FY2023 | Mar 31, 2023 | $525.27K | -85.7% |
| Q4 FY2022 | Dec 31, 2022 | $339.97K | -87.2% |
| Q3 FY2022 | Sep 30, 2022 | $381.57K | -75.1% |
| Q2 FY2022 | Jun 30, 2022 | $975.58K | -15.9% |
| Q1 FY2022 | Mar 31, 2022 | $3.68M | +136.4% |
| Q4 FY2021 | Dec 31, 2021 | $2.67M | – |
| Q3 FY2021 | Sep 30, 2021 | $1.53M | – |
| Q2 FY2021 | Jun 30, 2021 | $1.16M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.56M | – |